Friday, October 28, 2011

Medivation pins hopes on prostate cancer drug

Medivation Inc. is getting another shot with another pill.
The San Francisco-based drug developer, which lost nearly 80 percent of its value after a highly touted Alzheimer’s disease treatment in March 2010 failed a late-stage clinical trial, will receive make-or-break data on an experimental prostate cancer treatment sometime over the next nine weeks.

No comments:

Post a Comment